(35 Total References)
The interest in secretin began in 1996, when Dr. Karoly S. Horvath, director of the pediatric gastrointestinal and nutrition laboratory at the University of Maryland, Baltimore, administered intravenous secretin while examining an autistic child with chronic diarrhea.
and associates gave secretin while assessing gastrointestinal complaints in two other autistic children, and reported "a dramatic improvement in their behavior, manifested by improved eye contact, alertness, and expansion of expressive language," in the next several weeks along with relief of gastrointestinal symptoms.
PLUK News April/May 1999
Interest in secretin began in 1996 when Dr. Karoly S. Horvath, director of the pediatric gastrointestinal and nutrition laboratory at the University of Maryland, Baltimore, administered intravenous secretin while examining an autistic child with chronic diarrhea.
gave secretin while assessing gastrointestinal complaints in two other children with autism and reported dramatic improvement in their behavior, manifested by improved eye contact, alertness, and expansion of expressive language in the next several weeks along with relief of gastrointestinal symptoms.
Secretin may influence blood flow in the brain and this may be the reason it has effects on the condition of autism.
Dr. Horvath reports that brain imaging studies in one of his
cases showed a marked postinfusion increase in cerebral blood flow in areas of the brain affecting language and social behavior.
Secretin may also activate receptors for a related hormone, vasoactive intestinal polypeptide, which is more widely distributed in the brain.
speculates that a single dose of secretin is unlikely to change the brain of a child with autism, but it could possible trigger a cascade of other neuropeptides in some children and in this way have more lasting effects.
will shortly finish data collection on a study of secretin use in 30 children.
Jornadas Internacionales del Autismo y Transtornos Generalizados del Desarollo
Dr. Karoly HorvathDr. Karoly Horvath is co-director of the University of Maryland Center for Celiac Research and associate professor of Pediatrics at the University of Maryland School of Medicine.He received his Ph.D. in Biochemistry from the Hungarian Academy of Sciences, and received his M.D. from Semmelweis University in Budapest.His
research has focused on the causes and effects of gastrointestinal disorders in children.Dr. Horvath
is the author of various publications in American and European scientific journals about Celiac disease and is highly recognized for his
research about the role of secretin administration in the treatment of autism.
Karoly Horvath, ...
Karoly Horvath, MD
Gastroenterology - Pediatric, Orlando, FL
Photo of Karoly Horvath, MD
Karoly Horvath, MD, PhD, joined the Arnold Palmer Hospital for Children Center for Pediatric Digestive Health and Nutrition in 2011.
Prior to moving to Orlando, Dr. Horvath served as the director of Nemours Children Celiac Center and the gastroenterology laboratory in A.I. DuPont Hospital for Children.
He is board certified in pediatric gastroenterology.
Additionally, Dr. Horvath
is a published author with numerous published articles and book chapters in a variety of gastroenterology topics.
He has dedicated many years to gastroenterology research and has taught at the University of Maryland and Hahnemann University in Philadelphia.
HealthScout-Death Rate Soars With Celiac Disease
"They followed the first-degree relatives because it is well known that one-in-12 relatives of a celiac disease patient will have the disease," says one celiac disease expert, Dr. Karoly Horvath, the director of the Pediatric Gastrointestinal & Nutrition Laboratory at the University of Maryland in Baltimore."And it's also known that a lot of these relatives are undiagnosed."
People with this disease must stay on gluten-free diets or risk damaging their small intestine and losing the ability to absorb nutrients.The study found that the death rate for those who failed to stick to a gluten-free diet was six times higher than for those who had.
An estimated one-in-4 ,700 Americans has been diagnosed with celiac disease.
Often the disease has no symptoms, Karoly
says."What happens with celiac disease is that it progresses very slowly.It's the first part of the 20 feet of intestine that absorbs nutrients and the disease progresses slowly down the length of the intestine.And if the lower intestine can compensate, which it does for a while, then there's no evident symptoms."
The study found the death rate was 2.6 times higher among those whose diagnosis was delayed for a year, and 3.8 times higher for those who weren't diagnosed for 10 years.
"The message in this study is that the more delayed the diagnosis of the disease, the more increased the mortality rate," Karoly
says."And there was a perception in the medical community in the U.S. that there was no such thing as celiac disease in this country, though that's changing now."
"We did a survey in the mid-90's asking celiac patients when they had their first symptoms and when they were diagnosed with the disease," Karoly
explains."The gap was 12 years.The problem is that, while using the screening techniques for celiac disease is quite routine in Europe, it has yet to be recognized as widely in the U.S."
What To Do
For more information on celiac disease, see the Celiac Disease Foundation
or the National Institute of Diabetes and Digestive and Kidney Diseases
...SOURCES: Interviews with Elaine Monarch, executive director, Celiac Disease Foundation, Studio City, Calif.; Karoly Horvath, M.D., Ph.D., director, Pediatric Gastrointestinal and Nutrition Laboratory, University of Maryland, Baltimore; Aug. 4, 2001, The Lancet